PA-BOOMI
6.8.2024 15:01:34 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced the release of a new report, “A Playbook for Crafting AI Strategy,” produced in collaboration with MIT Technology Review Insights. This comprehensive study — which includes a global survey of C-suite and senior data executives, including in-depth interviews conducted with business leaders on data and AI — sheds light on the current state of enterprise AI adoption, and offers actionable strategies for navigating the transformative landscape of artificial intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806027370/en/
Boomi Releases Strategic Playbook for Effective AI Adoption (Graphic: Business Wire)
As businesses grapple with ambitious AI predictions — such as PwC's forecast that AI could contribute an astounding $15.7 trillion to global GDP by 20301 — major hurdles remain in the journey from pilot projects to enterprise-wide deployment. As an example, just 5.4% of US businesses utilized AI to produce a product or service in 2024,2 signifying a pressing need for strategic and organizational shifts to leverage AI effectively.
Key findings from the report highlight the following trends and challenges:
- AI ambitions are substantial, but few have scaled beyond pilots. Fully 95% of companies surveyed are already using AI and 99% expect to in the future. But few organizations have graduated beyond pilot projects: 76% have deployed AI in just one to three use cases. As half of companies expect to fully deploy AI across all business functions within two years, this year is key to establishing foundations for enterprise-wide AI.
- AI-readiness spending is slated to rise significantly. Overall, AI spending in 2022 and 2023 was modest or flat for most companies, with only one in four increasing their spending by more than a quarter. That is set to change in 2024, with nine in ten respondents expecting to increase AI spending on data readiness (including platform modernization, cloud migration, and data quality) and in adjacent areas like strategy, cultural change, and business models. Four in ten expect to increase spending by 10 to 24%, and one-third expect to increase spending by 25 to 49%.
- Data liquidity is one of the most important attributes for AI deployment. The ability to seamlessly access, combine, and analyze data from various sources enables firms to extract relevant information and apply it effectively to specific business scenarios. It also eliminates the need to sift through vast data repositories, as the data is already curated and tailored to the task at hand.
- Data quality is a major limitation for AI deployment. Half of respondents cite data quality as the most limiting data issue in deployment. This is especially true for larger firms with more data and substantial investments in legacy IT infrastructure. Companies with revenues of over $10 billion are the most likely to cite both data quality and data infrastructure as limiters, suggesting that organizations presiding over larger data repositories find the problem substantially harder.
- Companies are not rushing into AI. Nearly all organizations (98%) say they are willing to forgo being the first to use AI if that ensures they can deliver it safely and securely. Governance, security, and privacy are the biggest brake on the speed of AI deployment, cited by 45% of respondents (and a full 65% of respondents from the largest companies).
“Over the last year, organizations have come to understand the power and potential of AI,” said Matt McLarty, CTO at Boomi. “This year, those organizations are seeking to shift from small pilots to enterprise-wide deployment of AI at scale.”
“A Playbook for Crafting AI Strategy” can assist with the next steps of an AI journey, offering the following principles as guidance:
- This is a critical year for building AI foundations. As organizations strive to meet ambitious short-term AI goals, they are discovering that having the right data foundation is critical. Organizations are doubling down on investments in data quality, data liquidity, and IT infrastructure.
- The highest-leverage AI use cases drive targeted, business-specific results. Although general-purpose generative AI use cases are increasingly simple to implement, they are equally available to competitors and customers. The most valuable use cases are those that create unique competitive advantages for the business.
- Financial considerations and partnerships are key. This year, the costs of AI — from GPUs to skilled talent to energy consumption — must be accounted for, and a realistic approach to measuring AI’s ROI must be developed. Because few organizations will go it alone when it comes to AI, making decisions about the right partners, vendors, and tools will be essential to most companies’ AI futures.
- Speed of AI adoption is being moderated by a realistic assessment of its risks. Organizations are rightly cautious about the risks posed by injudicious use of AI, and essentially all agree that caution is preferable to first-mover advantage when scaling AI. An emerging regulatory environment and a better understanding of how the risks of AI can be mitigated should serve to speed adoption.
“The biggest factor holding back AI implementation is not knowing where to start,” said Matt McLarty, CTO at Boomi. “You don’t actually have to be an expert on how to create generative AI in order to get value from generative AI. As organizations seek to harness AI's transformative potential, our report serves as a crucial playbook, guiding business leaders through the complexities of AI strategy formulation.”
Download the complete report, “A Playbook for Crafting AI Strategy.”
Additional Resources
- Learn more about the Boomi Enterprise Platform
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With a customer base exceeding 20,000 companies globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
__________________________
1 Sizing the prize: What’s the real value of AI for your business and how can you capitalise?” PwC, 2017, https://preview.thenewsmarket.com/Previews/PWC/DocumentAssets/476830.pdf.
2 Richard Vanderford, “Generative AI Isn’t Ubiquitous in the Business World—at Least Not Yet,” The Wall Street Journal, April 7, 2024, https://www.wsj.com/articles/generative-ai-isnt-ubiquitous-in-the-business-worldat-least-not-yet-07c07f01?mod=tech_lead_pos3.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806027370/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
